Therapeutic potential of TNF-related apoptosis-inducing ligand receptor antibodies

Bibliography

• WALCZAK H, DEGLI-ESPOSTI MA, JOHNSON RS et al: TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. Embo J. (1997) 16:5386–5397.
   PubMed Web of Science ®Google Scholar
• GRIFFITH TS, LYNCH DH: TRAIL: a molecule with multiple receptors and control mechanisms. Cup: Opin. bronunol. (1998) 10:559–563.
   PubMed Web of Science ®Google Scholar
• BODMERJL, HOLLER N, REYNARD S et al.: TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat. Cell Biol. (2000) 2:241–243.
   PubMed Web of Science ®Google Scholar
• SULIMAN A, LAM A, DATTA R, SRIVASTAVA RK: Intracellular mechanisms of TRAIL: apoptosis through mitochondrial-dependent and -independent pathways. Oncogene (2001) 20:2122–2133.
   PubMed Web of Science ®Google Scholar
• ••First proof of the involvement of mitochondria in TRAIL-induced apoptosis.
   Google Scholar
• GURA T: How TRAIL kills cancer cells, but not normal cells. Science (1997) 277:768.
   PubMed Web of Science ®Google Scholar
• FRENCH LE, TSCHOPP J: The TRAIL toselective tumor death. Nat. Med. (1999) 5:146–147.
   PubMed Web of Science ®Google Scholar
• WALCZAK H, MILLER RE, ARIAIL K et al: Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med. (1999) 5:157–163.
   PubMed Web of Science ®Google Scholar
• NAGATA S: Apoptosis by death factor. Cell (1997) 88:355–365.
   PubMed Web of Science ®Google Scholar
• ORLINICK JR, VAISHNAW AK, ELKON KB: Structure and function of Fas/Fas ligand. Int. Rev bronunol. (1999) 18:293–308.
   PubMedGoogle Scholar
• •• H.GIBSON SB, OYER R, SPALDING AC,37. ANDERSON SM, JOHNSON GL: Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL. Ma Cell Biol. (2000) 20:205–212.••
   Google Scholar
• ASHKENAZI A, PAT RC, FONG S et al.: Safety and antitumor activity of recombinant soluble Apo2 ligand. Gin. Invest. (1999) 104:155–162.
   PubMed Web of Science ®Google Scholar
• PANG, O'ROURKE K, CHINNAIYAN AM et at The receptor for the cytotoxic ligand TRAIL. Sdence (1997) 276:111–113.
   Google Scholar
• PAN G, NI J, WET YE YU G, GENTZ R, DIXIT VM: An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science (1997) 277:815–818.
   PubMed Web of Science ®Google Scholar
• SHERIDAN JP, MARSTERS SA, PITTI RIVI et al: Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science (1997) 277:818–821.
   PubMed Web of Science ®Google Scholar
• DEGLI-ESPOSTI MA, SMOLAK PJ, WALCZAK H et al.: Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. Exp. Med. (1997) 186:1165–1170.
   PubMed Web of Science ®Google Scholar
• DEGLI-ESPOSTI MA, DOUGALL WC, SMOLAK PJ, WAUGH JY, SMITH CA, GOODWIN RG: The novel receptor TRAIL-R4 induces NF-icB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity (1997) 7:813–820.
   PubMed Web of Science ®Google Scholar
• MARSTERS SA, SHERIDAN JP, PITTI RIVI et al.: A novel receptor for Apo2L/TRAIL contains a truncated death domain. Can: Bin/. (1997) 7:1003–1006.
   Google Scholar
• EMERY JG, MCDONNELL P, BURKE MB et al.: Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. Biol Chem. (1998) 273:14363–14367.
   Web of Science ®Google Scholar
• SRIVASTAVA RK: TRAIL/Apo-2L: mechanisms and clinical applications in cancer. Neoplasia (2001) 3:535–546.
   PubMed Web of Science ®Google Scholar
• ••A comprehensive review on TRAILsignalling.
   Google Scholar
• LEBLANC HN, ASHKENAZI A: Apo2L/TRAIL and its death and decoy receptors. Cell Death Diller. (2003) 10:66–75.
   PubMed Web of Science ®Google Scholar
• GREEN DR, REED JC: Mitochondria and apoptosis. Science (1998) 281:1309–1312.
   PubMed Web of Science ®Google Scholar
• REED JC: Apoptosis-targeted therapies for cancer. Cancer Cell (2003) 3:17–22.
   PubMed Web of Science ®Google Scholar
• ••A comprehensive review on apoptosis.
   Google Scholar
• KANDASAMY K, SRINIVASULA SM, ALNEMRI ES et al.: Involvement of proapoptotic molecules Box and Bak in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced mitochondrial disruption and apoptosis: differential regulation of cytochrome c and Smac/DIABLO release. Cancer Res. (2003) 63:1712–1721.
   PubMed Web of Science ®Google Scholar
• KIM EJ, SULIMAN A, LAM A, SRIVASTAVA RK: Failure of Bc1-2 to block mitochondrial dysfunction during TRAIL-induced apoptosis. hat. J. Oncol (2001) 18:187–194.
   Web of Science ®Google Scholar
• SRIVASTAVA RK: Intracellular mechanismsof TRAIL and its role in cancer therapy. Ma Cell Biol. Res. Comm. (2000) 4:67–75.
   PubMedGoogle Scholar
• CHINNAIYAN AM, PRASAD U, SHANKAR S et al: Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc. Natl. Acad. Sci. USA (2000) 97:1754–1759.
   PubMed Web of Science ®Google Scholar
• NIMMANAPALLI R, PERKINS CL, ORLANDO M, O'BRYAN E, NGUYEN D, BHALLA KN: Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels. Cancer Res. (2001) 61:759–763.
   PubMed Web of Science ®Google Scholar
• BARTEK J, IGGO R, GANNON J, LANE DP: Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene (1990) 5:893–899.
   PubMed Web of Science ®Google Scholar
• BARTEK J, BARTKOVA J, VOJTESEK B et al.: Patterns of expression of the p53 tumour suppressor in human breast tissues and tumours in situ and in vitro. Int. J. Cancer (1990) 46:839–844.
   PubMed Web of Science ®Google Scholar
• VOJTESEK B, LANE DP: Regulation of p53 protein expression in human breast cancer cell lines.' Cell Sci (1993) 105:607–612.
   PubMed Web of Science ®Google Scholar
• KEANE MM, ETTENBERG SA, NAU MM, RUSSELL EK, LIPKOWITZ S: Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res. (1999) 59:734–741.
   PubMed Web of Science ®Google Scholar
• NAGANE M, PAN G, WEDDLE JJ, DIXIT VM, CAVENEE WK, HUANG HJ: Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. Cancer Res (2000) 60:847–853.
   PubMed Web of Science ®Google Scholar
• ASHKENAZI A, DIXIT VM: Death receptors: signaling and modulation. Science (1998) 281:1305–1308.
   PubMed Web of Science ®Google Scholar
• LEVERKUS M, NEUMANN M, MENGLING T et al: Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes. Cancer Res (2000) 60:553–559.
   PubMed Web of Science ®Google Scholar
• GRIFFITH TS, CHIN WA, JACKSON GC, LYNCH DH, KUBIN MZ: Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. Immunol (1998) 161:2833–2840.
   Web of Science ®Google Scholar
• RAVI R, BEDI GC, ENGSTROM LW et al: Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-1(B. Nat. Cell Biol. (2001) 3:409-416. CHEN X, KANDASAMY K, SRIVASTAVA RK: Differential roles of RelA (p65) and c-Rel subunits of nuclear factor kappa B in tumor necrosis factor-related apoptosis-inducing ligand signaling. Cancer Res. (2003) 63:1059-1066. Differential roles of Nfic.13 in signalling.
   Google Scholar
• KEOGH SA, WALCZAK H, BOUCHIER-HAYES L, MARTIN SJ: Failure of Bc1-2 to block cytochrome c redistribution during TRAIL-induced apoptosis. FEBS Led (2000) 471:93–98.
   PubMed Web of Science ®Google Scholar
• SUN SY, YUE P, ZHOU JY et al.: Overexpression of Bc1-2 blocks TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in human lung cancer cells. Biochem. Biophys. Res. Commun. (2001) 280:788–797.
   PubMed Web of Science ®Google Scholar
• IBRAHIM SM, RINGEL J, SCHMIDT C eta]: Pancreatic adenocarcinoma cell lines show variable susceptibility to TRAIL-mediated cell death. Pancreas (2001) 23:72–79.
   PubMed Web of Science ®Google Scholar
• MUNSHI A, PAPPAS G, HONDA T et al.: TRAIL (Apo-2L) induces apoptosis in human prostate cancer cells that is inhibitable by Bc1-2. Oncogene (2001) 20:3757–3765.
   PubMed Web of Science ®Google Scholar
• LEBLANC H, LAWRENCE D, VARFOLOMEEV E et al.: Tumor-cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bc1-2 homolog Bax. Nat. Med. (2002) 8:274–281.
   PubMed Web of Science ®Google Scholar
• CHEN X, THAKKAR H, TYAN F et al: Constitutively active Mt is an important regulator of TRAIL sensitivity in prostate cancer. Oncogene (2001) 20:6073–6083.
   PubMed Web of Science ®Google Scholar
• NESTEROV A, LU X, JOHNSON M, MILLER GJ, IVASHCHENKO Y, KRAFT AS: Elevated akt activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis. j Biol. Chem (2001) 276:10767–10774.
   PubMed Web of Science ®Google Scholar
• KANDASAMY K, SRIVASTAVA RK: Role of the phosphatidylinositol 3'-kinase/PTEN/ Akt kinase pathway in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in non-small cell lung cancer cells. Cancer Res. (2002) 62:4929–4937.
   PubMed Web of Science ®Google Scholar
• FULDA S, WICK W, WELLER M, DEBATIN KM: Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat. Med. (2002) 8:808–815.
   PubMed Web of Science ®Google Scholar
• NG CP, BONAVIDA B: X-linked inhibitorof apoptosis (XIAR) blocks Apo2 ligand/ tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis of prostate cancer cells in the presence of mitochondrial activation: sensitization by overexpression of second mitochondria-derived activator of caspaseidirect IAP-binding protein with low pl (Smac/ DIABLO). Mol. Cancer Ther. (2002) 1:1051–1058.
   PubMed Web of Science ®Google Scholar
• YANG L, MASHIMA T, SATO S et al.: Predominant suppression of apoptosome by inhibitor of apoptosis protein in non-small cell lung cancer H460 cells: therapeutic effect of a novel polyarginine-conjugated Smac peptide. Cancer Res. (2003) 63:831–837.
   PubMed Web of Science ®Google Scholar
• GORES GJ, KAUFMANN SH: Is TRAIL hepatotoxic? Hepatology (2001) 34:3–6.
   PubMed Web of Science ®Google Scholar
• JO M, KIM TH, SEOL DW et al: Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat. Med. (2000) 6:564–567.
   PubMed Web of Science ®Google Scholar
• GRIFFITH TS, RAUCH CT, SMOLAK PJ et al.: Functional analysis of TRAIL receptors using monoclonal antibodies. Immunol. (1999) 162:2597–2605.
   Web of Science ®Google Scholar
• •Use of monoclonal antibodies of TRAIL receptors.
   Google Scholar
• ICHIKAWA K, LIU W, ZHAO L et al: Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocytecytotoxicity. Nat. Med. (2001) 7:954–960.
   PubMed Web of Science ®Google Scholar
• •Demonstration that anti-human DR5 antibody may be safe in humans.
   Google Scholar
• LAWRENCE D, SHAHROKH Z, MARSTERS S et al.: Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat. Med. (2001) 7:383–385.
   PubMed Web of Science ®Google Scholar
• QIN, J, CHATURVEDI V, BONISH B, NICKOLOFF BJ: Avoiding premature apoptosis of normal epidermal cells. Nat. Med. (2001) 7:385–386.
   PubMed Web of Science ®Google Scholar
• ZAMAI L, SECCHIERO P, PIERPAOLI S et al: TNF-related apoptosis-inducing ligand (TRAIL) as a negative regulator of normal human erythropoiesis. Blood (2000) 95:3716–3724.
   PubMed Web of Science ®Google Scholar
• OKADA H, KOBUNE F, SATO TA et al.:Extensive lymphopenia due to apoptosis of uninfected lymphocytes in acute measles patients. Arch. Virol. (2000) 145:905–920.
   PubMed Web of Science ®Google Scholar
• NITSCH R, BECHMANN I, DEISZ RA et al: Human brain-cell death induced by tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL). Lancet (2000) 356:827–828.
   PubMed Web of Science ®Google Scholar
• BODMER JL, MEIER P, TSCHOPP J, SCHNEIDER P: Cysteine 230 is essential for the structure and activity of the cytotoxic ligand TRAIL. j Biol. Chem (2000) 275(27):20632–20637.
   PubMed Web of Science ®Google Scholar
• NICHOLSON DW: From bench to clinic with apoptosis-based therapeutic agents. Nature (2000) 407(6805):810–816.
   PubMed Web of Science ®Google Scholar